Na Qin

2.4k total citations · 1 hit paper
85 papers, 1.2k citations indexed

About

Na Qin is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Na Qin has authored 85 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 33 papers in Pulmonary and Respiratory Medicine and 30 papers in Cancer Research. Recurrent topics in Na Qin's work include Lung Cancer Treatments and Mutations (27 papers), RNA modifications and cancer (20 papers) and Cancer-related molecular mechanisms research (19 papers). Na Qin is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), RNA modifications and cancer (20 papers) and Cancer-related molecular mechanisms research (19 papers). Na Qin collaborates with scholars based in China, United States and Canada. Na Qin's co-authors include Juncheng Dai, Hongxia Ma, Hongbing Shen, Zhibin Hu, Guangfu Jin, Xi Li, Jing Zhou, Cheng Wang, Wen Zhou and Meng Zhu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Na Qin

76 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The burden of Gastric Cancer and possible risk factors from 1990 to 2021, and projections until 2035: findings from the Global Burden of Disease Study 2021

2025 16 citations Na Qin et al. profile →

Peers

Countries citing papers authored by Na Qin

Since Specialization

Citations

This map shows the geographic impact of Na Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Qin more than expected).

Fields of papers citing papers by Na Qin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Qin. The network helps show where Na Qin may publish in the future.

Co-authorship network of co-authors of Na Qin

This figure shows the co-authorship network connecting the top 25 collaborators of Na Qin. A scholar is included among the top collaborators of Na Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Qin. Na Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RNA m ¹ A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target 2025 ·Cancer Communications ·Xiaoting Zhang, Na Qin, Fenfen Ji, Hao Su, (unknown), Hongyan Chen, Dan Huang, Qing Li, Jing Ren, Weixin Liu, Yifei Wang, (unknown), Jiabin Wu, (unknown), Zongwei Cai, Matthew T.V. Chan, (unknown), Jun Yu, Huarong Chen	1
2	Effects of minocycline on patients with acute anterior circulation ischaemic stroke undergoing intravenous thrombectomy (MIST-A): the study protocol for a multicentre, prospective, randomised, open-label, blinded-endpoint trial 2024 ·BMJ Open ·(unknown), Jingjing Zhao, (unknown), Wei Dong, Yao Li, (unknown), Hao Zhu, Wenyu Liu, Huiping Zhang, (unknown), (unknown), (unknown), Bin Wang, (unknown), Na Qin, Wen Jiang	1
3	Systematic identification of pathogenic variants of non-small cell lung cancer in the promoters of DNA-damage repair genes 2024 ·EBioMedicine ·Mingxing An, (unknown), Jun Xiang, Yang Li, Pengcheng Qiu, Yuliang Tang, Xinyue Liu, Yayun Gu, Na Qin, Yuanlin He, Meng Zhu, Yue Jiang, Juncheng Dai, Guangfu Jin, Hongxia Ma, Cheng Wang, Zhibin Hu, Hongbing Shen	0
4	Phosphorylation of USP27X by GSK3β maintains the stability and oncogenic functions of CBX2 2023 ·Cell Death and Disease ·(unknown), (unknown), (unknown), Xiaodong Cao, Bing Li, (unknown), (unknown), (unknown), Huiwen Zhang, Na Qin, (unknown), Dongfeng Wang, Qi Xiao, Yutong Wang, (unknown), Shuang Zhang, (unknown), (unknown), (unknown)	6
5	Distinct DNA methylation signatures associated with blood lipids as exposures or outcomes among survivors of childhood cancer: a report from the St. Jude lifetime cohort 2023 ·Clinical Epigenetics ·Qian Dong, (unknown), Nan Song, Na Qin, (unknown), (unknown), Kyla Shelton, John Easton, Heather L. Mulder, (unknown), Geoffrey Neale, Emily Walker, Qian Li, I‐Chan Huang, Jinghui Zhang, Hui Wang, Melissa M. Hudson, Leslie L. Robison, Kirsten K. Ness, Zhaoming Wang	2
6	Gene amplification‐driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A‐YTHDF2‐dependent in lung adenocarcinoma 2022 ·Cancer Communications ·Chang Zhang, Qi Sun, Xu Zhang, Na Qin, Zhening Pu, Yayun Gu, Caiwang Yan, Meng Zhu, Juncheng Dai, Cheng Wang, Ni Li, Guangfu Jin, Hongxia Ma, Zhibin Hu, Erbao Zhang, Fengwei Tan, Hongbing Shen	51
7	Single‐cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma 2022 ·Hepatology ·Yuanlin He, (unknown), Guannan Zhang, Yu Jin, Nanxi Wang, (unknown), Changxian Li, Xiaohuan Guo, Na Qin, Juncheng Dai, Yun Chen	39
8	Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry 2020 ·Cancer Research ·Yadav Sapkota, Na Qin, Matthew J. Ehrhardt, Zhaoming Wang, Yan Chen, Carmen L. Wilson, Jeremie H. Estepp, (unknown), Jane S. Hankins, Paul W. Burridge, John L. Jefferies, Jinghui Zhang, Melissa M. Hudson, Leslie L. Robison, Gregory T. Armstrong, Daniel A. Mulrooney, Yutaka Yasui	24
9	Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer 2019 ·Breast Cancer Research and Treatment ·Chengxiao Yu, Na Qin, Zhening Pu, Ci Song, Cheng Wang, Jiaping Chen, Juncheng Dai, Hongxia Ma, Tao Jiang, Yue Jiang	3
10	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation 2019 ·Interdisciplinary Sciences Computational Life Sciences ·Li Ma, Jialin Lv, Yujie Dong, Xinyong Zhang, Xi Li, Hui Zhang, Jingying Nong, Quan Zhang, Na Qin, Xinjie Yang, Jinghui Wang, Shucai Zhang	21
11	Evaluation of CpG-SNPs in miRNA promoters and risk of breast cancer 2018 ·Gene ·Jiaping Chen, Yue Jiang, Jing Zhou, Sijun Liu, Na Qin, Jiangbo Du, Guangfu Jin, Zhibin Hu, Hongxia Ma, Hongbing Shen, Juncheng Dai	17
12	Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population 2017 ·Molecular Carcinogenesis ·Yue Jiang, (unknown), Fei Chen, Na Qin, (unknown), Jin Zhou, Tao Jiang, Zhening Pu, (unknown), Jiaping Chen, Juncheng Dai, Hongxia Ma, Guangfu Jin, Zhibin Hu, Hao Yu, Hongbing Shen	9
13	The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer 2017 ·Scientific Reports ·Dan Zhao, Xuejing Chen, Na Qin, Dan Su, Lijuan Zhou, Quan Zhang, Xi Li, Xinyong Zhang, Mulan Jin, Jinghui Wang	39
14	A functional SNP rs1892901 in FOSL1 is associated with gastric cancer in Chinese population 2017 ·Scientific Reports ·Wenjie Liu, Tian Tian, Li Liu, Jiangbo Du, Yayun Gu, Na Qin, Caiwang Yan, Zhaoming Wang, Juncheng Dai, Zhining Fan	7
15	Local intra-articular injection of resveratrol delays cartilage degeneration in C57BL/6 mice by inducing autophagy via AMPK/mTOR pathway 2017 ·Journal of Pharmacological Sciences ·Na Qin, (unknown), Wuyin Li, (unknown), (unknown), Zhuang Qian, Shufang Wu	79
16	[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified]. 2015 ·SHILAP Revista de lepidopterología ·Xi Li, Na Qin, Jinghui Wang, Xinjie Yang, Xinyong Zhang, Jialin Lv, (unknown), Hui Zhang, Jingying Nong, Quan Zhang, Shucai Zhang	6
17	Human Leukocyte Antigen DQB1 (HLA-DQB1) Polymorphisms and the Risk for Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis 2015 ·PLoS ONE ·Pengpeng Jin, Lili Sun, (unknown), Na Qin, (unknown), Xia Feng, Li Li, Lijuan Liu, Xuedong Liu, Gang Zhao, Wen Wang, Yanchun Deng, Shuangxing Hou	21
18	Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR 2014 ·PLoS ONE ·Jinghui Wang, Yiran Cai, Yujie Dong, Jingying Nong, Lijuan Zhou, Guimei Liu, Dan Su, Xi Li, Shafei Wu, Xuejing Chen, Na Qin, Xuan Zeng, Haiqing Zhang, Zongde Zhang, Shucai Zhang	47
19	Efficacy of Icotinib treatment in patients with stage IIIb/IV non‐small cell lung cancer 2013 ·Thoracic Cancer ·Na Qin, Xinjie Yang, Quan Zhang, Xi Li, Hui Zhang, Jialin Lv, (unknown), Jinghui Wang, Shucai Zhang	7
20	Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology 2013 ·Journal of Molecular Diagnostics ·Hui Zhang, Deruo Liu, Shanqing Li, (unknown), Xinjie Yang, Xi Li, Quan Zhang, Na Qin, (unknown), Lifen Ren‐Heidenreich, Huiyi Yang, (unknown), Xinyong Zhang, Jingying Nong, (unknown), Shucai Zhang	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact